

Paola Rogliani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1341783/publications.pdf>

Version: 2024-02-01

368
papers

8,814
citations

53789

45
h-index

79691

73
g-index

371
all docs

371
docs citations

371
times ranked

8914
citing authors

#	ARTICLE	IF	CITATIONS
1	Lessons from peculiar cases of anaphylaxis: why allergists should be prepared for the unexpected. <i>European Annals of Allergy and Clinical Immunology</i> , 2022, 54, 99.	1.0	3
2	The Future of Bronchodilators in COPD and Asthma. <i>Archivos De Bronconeumologia</i> , 2022, 58, 107-108.	0.8	4
3	Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 357-365.	2.5	3
4	Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis. <i>Drugs</i> , 2022, 82, 1-13.	10.9	12
5	Synergy across the drugs approved for the treatment of asthma. <i>Minerva Medica</i> , 2022, 113, .	0.9	6
6	Beyond Dual Bronchodilation – Triple Therapy, When and Why. <i>International Journal of COPD</i> , 2022, Volume 17, 165-180.	2.3	9
7	Efficacy of respiratory tele-rehabilitation in COPD patients: Systematic review and meta-analysis. <i>Monaldi Archives for Chest Disease</i> , 2022, , .	0.6	10
8	First Case of a COVID-19 Patient Infected by Delta AY.4 with a Rare Deletion Leading to a N Gene Target Failure by a Specific Real Time PCR Assay: Novel Omicron VOC Might Be Doing Similar Scenario?. <i>Microorganisms</i> , 2022, 10, 268.	3.6	12
9	COVID-19 lockdown, personal protective equipment, hyper-hygiene and allergy. <i>European Annals of Allergy and Clinical Immunology</i> , 2022, , .	1.0	0
10	Use of face masks and allergic rhinitis from ragweed: Why mention only total pollen count and not air pollution levels?. <i>International Forum of Allergy and Rhinology</i> , 2022, 12, 886-888.	2.8	1
11	Clinical Interpretation of Efficacy Outcomes in Pharmacological Studies on Triple Fixed-Dose Combination Therapy for Uncontrolled Asthma: Assessment of IRIDIUM and ARGON Studies. <i>Journal of Experimental Pharmacology</i> , 2022, Volume 14, 1-5.	3.2	4
12	The future of inhalation therapy in chronic obstructive pulmonary disease. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022, 3, 100092.	3.6	8
13	Prescribing the right therapy for the treatment of chronic cough: a critical focus on current and investigational options. <i>Expert Opinion on Pharmacotherapy</i> , 2022, , 1-4.	1.8	0
14	Inflammatory and contractile profile in LPS-challenged equine isolated bronchi: Evidence for IL-6 as a potential target against AHR in equine asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2022, 73-74, 102125.	2.6	6
15	Dual bronchodilation for the treatment of COPD: From bench to bedside. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3657-3673.	2.4	10
16	Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 565-577.	3.4	6
17	A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 269-283.	3.1	0
18	Systematic Literature Review of Treatments Used for Refractory or Unexplained Chronic Cough in Adults. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
19	The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review. <i>European Respiratory Review</i> , 2022, 31, 210196.	7.1	8
20	Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today?. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 917-927.	1.8	4
21	Stem Cell-Based Regenerative Therapy and Derived Products in COPD: A Systematic Review and Meta-Analysis. <i>Cells</i> , 2022, 11, 1797.	4.1	7
22	An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1205-1216.	1.8	4
23	Muscarinic receptor antagonists and airway inflammation: A systematic review on pharmacological models. <i>Heliyon</i> , 2022, 8, e09760.	3.2	2
24	The 5T approach in asthma: Triple Therapy Targeting Treatable Traits. <i>Respiratory Medicine</i> , 2022, 200, 106915.	2.9	11
25	Unmet Needs and the Future of Asthma-Chronic Pulmonary Obstructive Disease Overlap. <i>Immunology and Allergy Clinics of North America</i> , 2022, , .	1.9	3
26	Radiological pitfalls associated with the diagnosis of usual interstitial pneumonia pattern on high-resolution computed tomography and associated findings: experience from a single Italian center. <i>Acta Radiologica</i> , 2021, 62, 619-627.	1.1	2
27	Depressive and anxiety symptoms in patients with SARS-CoV2 infection. <i>Journal of Affective Disorders</i> , 2021, 278, 339-340.	4.1	11
28	Advances in understanding of mechanisms related to increased cardiovascular risk in COPD. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 59-70.	2.5	8
29	Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 561-568.	2.5	27
30	Guidance on nebulization during the current COVID-19 pandemic. <i>Respiratory Medicine</i> , 2021, 176, 106236.	2.9	35
31	Prospects for severe asthma treatment. <i>Current Opinion in Pharmacology</i> , 2021, 56, 52-60.	3.5	17
32	Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa588.	0.9	27
33	Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow's milk aspiration. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100010.	3.6	4
34	Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. <i>Drug Safety</i> , 2021, 44, 273-290.	3.2	25
35	Mepolizumab Effectiveness and Allergic Status in Real Life. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 311-318.	2.1	4
36	Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 611-620.	1.8	10

#	ARTICLE	IF	CITATIONS
37	Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 143-152.	2.5	29
38	Exploring the Relationship between Disease Awareness and Outcomes in Patients with Chronic Obstructive Pulmonary Disease. <i>Respiration</i> , 2021, 100, 291-297.	2.6	7
39	Electrocardiographic modifications and cardiac involvement in COVID-19 patients: results from an Italian cohort. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 190-196.	1.5	3
40	Drug interaction and chronic obstructive respiratory disorders. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100009.	3.6	9
41	Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies. <i>European Respiratory Journal</i> , 2021, 58, 2004233.	6.7	31
42	Happy hypoxemia, or blunted ventilation?. <i>Respiratory Research</i> , 2021, 22, 4.	3.6	9
43	Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma. <i>Clinical Respiratory Journal</i> , 2021, 15, 237-243.	1.6	4
44	Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 891-906.	5.0	7
45	The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review. <i>International Journal of COPD</i> , 2021, Volume 16, 257-279.	2.3	17
46	Comparative studies of dual bronchodilation in COPD. <i>Monaldi Archives for Chest Disease</i> , 2021, 91, .	0.6	3
47	Treatable Mechanisms in Asthma. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 111-121.	3.8	17
48	Inhaled long-acting muscarinic antagonists in asthma – A narrative review. <i>European Journal of Internal Medicine</i> , 2021, 85, 14-22.	2.2	18
49	Can placebo challenge test (inducing a “nocebo effect”) be a suitable model to assess stress-induced bronchial obstruction? Suggestions from the multidisciplinary Working Groups “Stress-Asthma” and “AAIITO Regione Campania”. <i>European Annals of Allergy and Clinical Immunology</i> , 2021, 53, 284.	1.0	0
50	New Avenues for Phosphodiesterase Inhibitors in Asthma. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 291-302.	3.2	17
51	Sex differences in COPD management. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 323-332.	3.1	16
52	SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. <i>Vaccines</i> , 2021, 9, 227.	4.4	47
53	Response to letter to the editor. Again on IMPACT: exacerbation after abrupt discontinuation of ICS and pneumonia in fluticasone furoate-containing FDCs. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 943-945.	1.8	0
54	Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials. <i>Vaccines</i> , 2021, 9, 341.	4.4	24

#	ARTICLE	IF	CITATIONS
55	Mortality in ETHOS: A Question of "Power". American Journal of Respiratory and Critical Care Medicine, 2021, 203, 926-927.	5.6	3
56	Quasibar minimalist lung volume reduction surgery. European Journal of Cardio-thoracic Surgery, 2021, 60, 598-606.	1.4	5
57	Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom. Journal of Clinical Medicine, 2021, 10, 1607.	2.4	21
58	Management of COPD patients during COVID: difficulties and experiences. Expert Review of Respiratory Medicine, 2021, 15, 1025-1033.	2.5	4
59	Step-up and step-down approaches in the treatment of asthma. Expert Review of Respiratory Medicine, 2021, 15, 1159-1168.	2.5	9
60	Disputes over the production and dissemination of misinformation in the time of COVID-19. Respiratory Medicine, 2021, 182, 106380.	2.9	4
61	Assessment of self-reported and objective daytime sleepiness in adult-onset myotonic dystrophy type 1. Journal of Clinical Sleep Medicine, 2021, 17, 2383-2391.	2.6	5
62	Atherogenic Dyslipidemia on Admission Is Associated With Poorer Outcome in People With and Without Diabetes Hospitalized for COVID-19. Diabetes Care, 2021, 44, 2149-2157.	8.6	20
63	Current long-acting muscarinic antagonists for the treatment of asthma. Expert Opinion on Pharmacotherapy, 2021, 22, 1-15.	1.8	1
64	Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence. International Journal of Molecular Sciences, 2021, 22, 7132.	4.1	6
65	Sex differences in excessive oral corticosteroid exposure in poor adherent adult asthmatics overusing short-acting β_2 agonists. Minerva Medica, 2021, , .	0.9	0
66	Face masks during COVID-19 pandemic lockdown and self-reported seasonal allergic rhinitis symptoms. Rhinology, 2021, 59, 0-0.	1.3	5
67	Use of Thiols in the Treatment of COVID-19: Current Evidence. Lung, 2021, 199, 335-343.	3.3	16
68	Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102050.	2.6	7
69	An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease. Biologics: Targets and Therapy, 2021, Volume 15, 363-374.	3.2	10
70	Which LABA/LAMA should be chosen in COPD patients in real life?. Pulmonary Pharmacology and Therapeutics, 2021, 71, 102076.	2.6	3
71	Incidence of pneumomediastinum in COVID-19: A single-center comparison between 1st and 2nd wave. Respiratory Investigation, 2021, 59, 661-665.	1.8	14
72	Multi-walled carbon nanotubes induce airway hyperresponsiveness in human bronchi by stimulating sensory C-fibers and increasing the release of neuronal acetylcholine. Expert Review of Respiratory Medicine, 2021, 15, 1473-1481.	2.5	5

#	ARTICLE	IF	CITATIONS
73	The Impact of Monoclonal Antibodies on Airway Smooth Muscle Contractility in Asthma: A Systematic Review. <i>Biomedicines</i> , 2021, 9, 1281.	3.2	13
74	Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways. <i>Pharmacological Research</i> , 2021, 172, 105801.	7.1	18
75	Controversy surrounding the Sputnik V vaccine. <i>Respiratory Medicine</i> , 2021, 187, 106569.	2.9	28
76	Editorial overview: Respiratory: Pulmonary pharmacologyâ€œThe emergence of new treatments in pulmonary medicine is finally providing real therapeutic perspectives. <i>Current Opinion in Pharmacology</i> , 2021, 60, 54-58.	3.5	3
77	SMART for the treatment of asthma: A network meta-analysis of real-world evidence. <i>Respiratory Medicine</i> , 2021, 188, 106611.	2.9	9
78	Reply to Han et al.: impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 579-581.	2.5	4
79	Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients. <i>Monaldi Archives for Chest Disease</i> , 2021, , .	0.6	3
80	Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review. <i>Respiratory Medicine</i> , 2021, 189, 106639.	2.9	4
81	Blood Eosinophils in Chronic Obstructive Pulmonary Disease: Is There Enough Evidence?. <i>US Respiratory & Pulmonary Diseases</i> , 2021, 6, 31.	0.2	1
82	Validation of the risk stratification score in idiopathic pulmonary fibrosis: study protocol of a prospective, multi-centre, observational, 3-year clinical trial. <i>BMC Pulmonary Medicine</i> , 2021, 21, 396.	2.0	0
83	Use of face masks and allergic nasal symptoms: Why not mention pollen count and air pollution data?. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2021, , 103363.	1.3	0
84	Highlights of high-resolution computed tomography imaging in evaluation of complications and co-morbidities in idiopathic pulmonary fibrosis. <i>Acta Radiologica</i> , 2020, 61, 204-218.	1.1	0
85	Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle <i>ex vivo</i> . <i>British Journal of Pharmacology</i> , 2020, 177, 1150-1163.	5.4	47
86	Severe Asthma and Biological Therapy: When, Which, and for Whom. <i>Pulmonary Therapy</i> , 2020, 6, 47-66.	2.2	63
87	A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 60, 101883.	2.6	7
88	The impact of comorbidities on severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 47-55.	2.6	40
89	Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent. <i>Drugs</i> , 2020, 80, 1799-1809.	10.9	21
90	Expression profiles of the SARS-CoV-2 host invasion genes in nasopharyngeal and oropharyngeal swabs of COVID-19 patients. <i>Heliyon</i> , 2020, 6, e05143.	3.2	23

#	ARTICLE	IF	CITATIONS
91	Real-life Mepolizumab effectiveness in severe eosinophilic asthmatics with nasal polyposis. <i>Respiratory Medicine and Research</i> , 2020, 78, 100791.	0.6	2
92	Use of mucolytics in COPD: A Delphi consensus study. <i>Respiratory Medicine</i> , 2020, 175, 106190.	2.9	4
93	The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. <i>Journal of Clinical Medicine</i> , 2020, 9, 2397.	2.4	6
94	Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. <i>Neurological Sciences</i> , 2020, 41, 2671-2674.	1.9	6
95	Pharmacological management of adult patients with acute respiratory distress syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2169-2183.	1.8	6
96	Are there pulmonary sequelae in patients recovering from COVID-19?. <i>Respiratory Research</i> , 2020, 21, 286.	3.6	42
97	COVID-19 and Genetic Variants of Protein Involved in the SARS-CoV-2 Entry into the Host Cells. <i>Genes</i> , 2020, 11, 1010.	2.4	88
98	Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 977-990.	3.1	10
99	<p>Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review</p>. <i>Journal of Experimental Pharmacology</i> , 2020, Volume 12, 233-253.	3.2	16
100	Targeting ILâ€5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab. <i>British Journal of Pharmacology</i> , 2020, 177, 4750-4765.	5.4	17
101	Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients. <i>Human Genomics</i> , 2020, 14, 29.	2.9	60
102	<p>Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 261-271.	0.7	6
103	Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. <i>Respiratory Medicine</i> , 2020, 171, 106114.	2.9	23
104	Advances with glucocorticoids in the treatment of asthma: state of the art. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2305-2316.	1.8	23
105	The latest on the role of LAMAs in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1288-1291.	2.9	17
106	<sc>HLA</sc> allele frequencies and susceptibility to <sc>COVID</sc>â€19 in a group of 99 Italian patients. <i>Hla</i> , 2020, 96, 610-614.	0.6	130
107	SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. <i>European Respiratory Journal</i> , 2020, 56, 2000625.	6.7	46
108	Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD). <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 723-738.	4.1	5

#	ARTICLE	IF	CITATIONS
109	Does bronchoscopy help the diagnosis in COVID-19 infection?. European Respiratory Journal, 2020, 56, 2001619.	6.7	27
110	<p>Day and Night Control of COPD and Role of Pharmacotherapy: A Review</p>. International Journal of COPD, 2020, Volume 15, 1269-1285.	2.3	12
111	What drives inhaler prescription for asthma patients? Results from a real-life retrospective analysis. Respiratory Medicine, 2020, 166, 105937.	2.9	6
112	A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2399-2401.	3.8	5
113	Pharmacology and Therapeutics of Bronchodilators Revisited. Pharmacological Reviews, 2020, 72, 218-252.	16.0	104
114	<p>Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study</p>. Risk Management and Healthcare Policy, 2020, Volume 13, 43-53.	2.5	11
115	Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. Expert Review of Respiratory Medicine, 2020, 14, 621-635.	2.5	2
116	Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Delivery, 2020, 17, 635-646.	5.0	39
117	The role of triple therapy in the management of COPD. Expert Review of Clinical Pharmacology, 2020, 13, 865-874.	3.1	7
118	TSLP Inhibitors for Asthma: Current Status and Future Prospects. Drugs, 2020, 80, 449-458.	10.9	51
119	Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life. Pulmonary Pharmacology and Therapeutics, 2020, 61, 101899.	2.6	46
120	Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2020, 17, 215-223.	1.6	2
121	Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control?. Monaldi Archives for Chest Disease, 2020, 90, .	0.6	2
122	Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain, Behavior, and Immunity, 2020, 88, 11-16.	4.1	159
123	As needed therapies in mild to severe asthma: a systematic review and network meta-analysis. , 2020, , .		2
124	Î±₁-Antitrypsin deficiency and chronic respiratory disorders. European Respiratory Review, 2020, 29, 190073.	7.1	47
125	<p>Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease</p>. Journal of Experimental Pharmacology, 2020, Volume 12, 559-574.	3.2	12
126	Anxiety depression and impaired asthma control in adolescents. Is an increased basal cholinergic tone a possible link. European Annals of Allergy and Clinical Immunology, 2020, 52, 190-192.	1.0	0

#	ARTICLE	IF	CITATIONS
127	Cardiovascular disease in COPD. , 2020, , 47-65.		1
128	PP399 Analysis Of Referral Patterns To Specialized Centers In Idiopathic Pulmonary Fibrosis To Define A New Regional Care Pathway. International Journal of Technology Assessment in Health Care, 2020, 36, 33-33.	0.5	0
129	Ergonomical Assessment of Three-Dimensional Versus Two-Dimensional Thoracoscopic Lobectomy. Seminars in Thoracic and Cardiovascular Surgery, 2020, 32, 1089-1096.	0.6	5
130	Triple Combination Inhalers in Chronic Obstructive Pulmonary Disease and Asthma. US Respiratory & Pulmonary Diseases, 2020, 5, 18.	0.2	4
131	Sleep and wake impairment in patients with SARS-CoV2 infection. Sleep Medicine, 2020, 73, 177-178.	1.6	0
132	Unmet needs and relationship between general practitioners (GPs) and allergists living in Campania region (southern Italy). European Annals of Allergy and Clinical Immunology, 2020, 52, 230.	1.0	1
133	Seasonal monitoring of serum IgE and blood eosinophil variability may lead to a better severe asthma phenotyping and to a correct biologic prescription. Journal of Biological Regulators and Homeostatic Agents, 2020, 34, 315-318.	0.7	3
134	Disease awareness in patients with COPD: measurement and extent. International Journal of COPD, 2019, Volume 14, 1-11.	2.3	9
135	Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice?. International Archives of Allergy and Immunology, 2019, 180, 142-143.	2.1	0
136	Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. Multidisciplinary Respiratory Medicine, 2019, 14, 25.	1.5	10
137	Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. Pulmonary Pharmacology and Therapeutics, 2019, 58, 101828.	2.6	16
138	CD71 ^{hi} Alveolar Macrophages in Idiopathic Pulmonary Fibrosis: A Look beyond the Borders of the Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1444-1446.	5.6	0
139	Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. Molecular Diagnosis and Therapy, 2019, 23, 603-614.	3.8	15
140	Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1643-1646.	3.8	8
141	Minimalist Thoracoscopic Biopsy of Interstitial Lung Disease. , 2019, , .		0
142	Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. Pulmonary Pharmacology and Therapeutics, 2019, 59, 101855.	2.6	16
143	Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. Pulmonary Pharmacology and Therapeutics, 2019, 59, 101841.	2.6	32
144	DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE.. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019065.	1.3	7

#	ARTICLE	IF	CITATIONS
145	Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β_2 -Agonists in COPD: Accumulating Evidence from Network Meta-Analyses. <i>Pulmonary Therapy</i> , 2019, 5, 117-126.	2.2	8
146	Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients. <i>Advances in Therapy</i> , 2019, 36, 3291-3298.	2.9	18
147	Ultra-LABAs for the treatment of asthma. <i>Respiratory Medicine</i> , 2019, 156, 47-52.	2.9	15
148	Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2019, 156, 78-84.	2.9	21
149	A potential role of triple therapy for asthma patients. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1079-1085.	2.5	18
150	Enfentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 827-833.	4.1	26
151	Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2019, 16, 215-226.	1.6	16
152	The prognostic role of Gender \times Age \times Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone. <i>Clinical Respiratory Journal</i> , 2019, 13, 166-173.	1.6	6
153	Monoclonal antibodies in severe asthma: is it worth it?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 517-520.	3.3	13
154	Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. <i>Respiratory Medicine</i> , 2019, 154, 86-92.	2.9	35
155	Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 452-463.	8.7	42
156	Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. <i>Respiratory Research</i> , 2019, 20, 104.	3.6	45
157	Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up. <i>Respiratory Medicine</i> , 2019, 153, 68-75.	2.9	3
158	Response. <i>Chest</i> , 2019, 155, 1079-1080.	0.8	1
159	Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. <i>Respiratory Medicine</i> , 2019, 153, 3-13.	2.9	35
160	Cardiovascular Disease in Chronic Respiratory Disorders and Beyond. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2178-2180.	2.8	8
161	Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 56, 39-50.	2.6	21
162	Bronchodilators in subjects with asthma-related comorbidities. <i>Respiratory Medicine</i> , 2019, 151, 43-48.	2.9	12

#	ARTICLE	IF	CITATIONS
163	Adding a LAMA to ICS/LABA Therapy. <i>Chest</i> , 2019, 155, 758-770.	0.8	65
164	Can f 5 as a suitable marker of dog allergy: Assess male dog exposure before banning it. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1657-1658.	2.9	6
165	The future of bronchodilation: looking for new classes of bronchodilators. <i>European Respiratory Review</i> , 2019, 28, 190095.	7.1	24
166	Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661988812.	2.6	12
167	Nonintubated surgical biopsy of undetermined interstitial lung disease: a multicentre outcome analysis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2019, 28, 744-750.	1.1	20
168	Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics. <i>World Allergy Organization Journal</i> , 2019, 12, 100081.	3.5	11
169	Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 737-750.	1.8	13
170	Pharmacological treatment and current controversies in COPD. <i>F1000Research</i> , 2019, 8, 1533.	1.6	27
171	Allergy in adolescent population (14-18 years) living in Campania region (Southern Italy). A multicenter study. <i>European Annals of Allergy and Clinical Immunology</i> , 2019, 51, 44.	1.0	3
172	The possible concomitant use of aeroallergen and food panels for skin prick testing might enhance the risk of generalized allergic reactions in children. <i>Turkish Journal of Pediatrics</i> , 2019, 61, 815.	0.6	2
173	Enfentrine. Dual phosphodiesterase PDE3/4 inhibitor, Treatment of COPD, Treatment of cystic fibrosis. <i>Drugs of the Future</i> , 2019, 44, 845.	0.1	1
174	Systemic pharmacotherapy. , 2019, , 215-222.		0
175	Critical interpretation of pairwise and network meta-analysis of randomized respiratory clinical trials. <i>AboutOpen</i> , 2019, 6, 55-61.	0.2	0
176	Why Are Allergens Not Detected in the Bronchoalveolar Lavage Fluid of Patients Undergoing Fiberoptic Bronchoscopy? Possible Explanations. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2019, 29, 472-473.	1.3	0
177	Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 88-94.	2.6	7
178	A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 509-517.	2.4	6
179	Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 429-435.	2.4	15
180	Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 50, 28-37.	2.6	13

#	ARTICLE	IF	CITATIONS
181	Is ICS+LAMA an alternative option to treat patients with COPD?. <i>Lancet Respiratory Medicine</i> , 2018, 6, 316-317.	10.7	7
182	Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 261-264.	2.5	26
183	Clinical effect of corticosteroids in asthma-affected horses: A quantitative synthesis. <i>Equine Veterinary Journal</i> , 2018, 50, 594-601.	1.7	11
184	Critical aspects in dog allergen immunotherapy (DAI). May Component Resolved Diagnosis (CRD) play a role in predicting the efficacy?. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1438-1441.	3.3	6
185	Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD. <i>Current Opinion in Pharmacology</i> , 2018, 40, 34-38.	3.5	20
186	Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 239-245.	3.3	9
187	Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 20-26.	2.6	2
188	Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. <i>Respiratory Research</i> , 2018, 19, 65.	3.6	30
189	The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 589-596.	2.4	13
190	Impact of doxofylline in COPD: A pairwise meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 51, 1-9.	2.6	17
191	Combining long-acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2018, 41, 546-554.	1.3	9
192	How does race/ethnicity influence pharmacological response to asthma therapies?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 435-446.	3.3	24
193	An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 43-54.	2.5	14
194	Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 103-112.	2.5	1
195	Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 48, 185-194.	2.6	20
196	Anxiety and asthma in youth. Is a stress-induced increased cholinergic tone the possible link?. <i>Pediatric Pulmonology</i> , 2018, 53, 128-129.	2.0	1
197	Staged unilateral lung volume reduction surgery: from mini-invasive to minimalist treatment strategies. <i>Journal of Thoracic Disease</i> , 2018, 10, S2754-S2762.	1.4	5
198	Occupational exposure to furry animals and asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 512-513.	1.0	1

#	ARTICLE	IF	CITATIONS
199	Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 1101-1111.	3.3	10
200	LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. <i>International Journal of COPD</i> , 2018, Volume 13, 3115-3130.	2.3	32
201	Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 2043-2053.	1.8	5
202	Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2018, 52, 1801586.	6.7	101
203	Indoor environmental interventions for furry pet allergens: How to decrease the degree of passive transport. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1808-1809.	3.8	0
204	LABA/LAMA Fixed Dose Combination in Chronic Obstructive Pulmonary Disease: The Impact on Health-Related Quality of Life. <i>Respiration</i> , 2018, 96, 370-381.	2.6	2
205	Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity. <i>Lung</i> , 2018, 196, 707-713.	3.3	9
206	Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells. <i>European Journal of Pharmacology</i> , 2018, 832, 114-119.	3.5	12
207	Multifaceted activity of N-acetylcysteine in chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 693-708.	2.5	30
208	Tiotropium could provide benefits in the early stage of COPD, but further studies are needed. <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 183-184.	3.5	1
209	Emerging antibacterial and antiviral drugs for treating respiratory tract infections. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 185-199.	2.4	2
210	Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. <i>BMC Pulmonary Medicine</i> , 2018, 18, 70.	2.0	53
211	Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach?. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 573-581.	4.1	18
212	Psychological Stress, Lung Function and Exacerbation Risk in COPD: Is an Increase of Cholinergic Tone a Possible Link?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2018, 15, 310-311.	1.6	7
213	N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. <i>Biomedicine and Pharmacotherapy</i> , 2018, 103, 1-8.	5.6	20
214	Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study. <i>Clinical and Molecular Allergy</i> , 2018, 16, 3.	1.8	15
215	Associated Pulmonary Hypertension Is an Independent Contributor to Exercise Intolerance in Chronic Fibrosing Interstitial Pneumonias. <i>Respiration</i> , 2018, 96, 543-551.	2.6	7
216	Anxiety and asthma in inner-city black adolescents: What could be the underestimated, possible connection?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1093-1094.	3.8	0

#	ARTICLE	IF	CITATIONS
217	Impact of doxofylline in COPD: a pair-wise meta-analysis. , 2018, , .		1
218	Dog allergy: can a prevalent or exclusive sensitization to Can f 5 be considered a lucky or negative event in "œreal life"? European Annals of Allergy and Clinical Immunology, 2018, 50, 283.	1.0	6
219	LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. European Respiratory Review, 2017, 26, 160043.	7.1	50
220	Role of muscarinic antagonists in asthma therapy. Expert Review of Respiratory Medicine, 2017, 11, 239-253.	2.5	27
221	Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respiratory Research, 2017, 18, 26.	3.6	60
222	Optimizing drug delivery in COPD: The role of inhaler devices. Respiratory Medicine, 2017, 124, 6-14.	2.9	131
223	Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression?. European Respiratory Journal, 2017, 49, 1602345.	6.7	11
224	Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis. Equine Veterinary Journal, 2017, 49, 710-717.	1.7	28
225	Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in "œreal life"? Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 535.	3.8	6
226	The Challenges of Precision Medicine in COPD. Molecular Diagnosis and Therapy, 2017, 21, 345-355.	3.8	37
227	Can a better patient phenotyping predict the efficacy of tiotropium in asthmatic adolescents?. Expert Opinion on Pharmacotherapy, 2017, 18, 833-835.	1.8	4
228	Indacaterol/Glycopyrronium Combination for COPD. Pulmonary Therapy, 2017, 3, 45-57.	2.2	2
229	An update on the pharmacotherapeutic management of lower respiratory tract infections. Expert Opinion on Pharmacotherapy, 2017, 18, 973-988.	1.8	9
230	Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine. EBioMedicine, 2017, 19, 14-15.	6.1	12
231	Adherence to COPD treatment: Myth and reality. Respiratory Medicine, 2017, 129, 117-123.	2.9	64
232	Bronchodilator therapy for chronic cough. Pulmonary Pharmacology and Therapeutics, 2017, 47, 88-92.	2.6	12
233	Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. Pulmonary Pharmacology and Therapeutics, 2017, 45, 148-158.	2.6	54
234	Relationship between oxytocin/vasopressin and latex in obstetric surgery: how to recognize (and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Immunology: in Practice, 2017, 5, 873.	3.8	3

#	ARTICLE	IF	CITATIONS
235	Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 44, 83-87.	2.6	11
236	Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. <i>Drugs</i> , 2017, 77, 721-732.	10.9	29
237	Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 627-636.	1.4	5
238	Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. <i>European Journal of Pharmacology</i> , 2017, 812, 147-154.	3.5	28
239	Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 526-532.	1.6	17
240	Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 552-563.	1.6	77
241	Anaphylaxis and intimate behaviour. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2017, 17, 350-355.	2.3	11
242	Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 940-951.	8.7	46
243	In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV1 than long-acting beta-agonists plus inhaled corticosteroids. <i>Evidence-Based Medicine</i> , 2017, 22, 183-184.	0.6	3
244	Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 641-647.	1.6	9
245	Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. <i>Respiratory Medicine</i> , 2017, 129, 189-198.	2.9	54
246	Tiotropium formulations and safety: a network meta-analysis. <i>Therapeutic Advances in Drug Safety</i> , 2017, 8, 17-30.	2.4	25
247	Multi-Dimensional Assessment in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2017, 152, A446.	0.8	0
248	Is the risk of developing atopic sensitization and bronchial asthma in animal laboratory workers preventable in well-defined susceptible individuals?. <i>Journal of Occupational Health</i> , 2017, 59, 310-311.	2.1	0
249	Acute exacerbations of COPD: risk factors for failure and relapse. <i>International Journal of COPD</i> , 2017, Volume 12, 2687-2693.	2.3	37
250	What Could the Role of Can f 5 Allergen Be in Dog- Sensitized Patients in "Real Life"? <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2017, 27, 397-398.	1.3	5
251	The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. <i>International Journal of COPD</i> , 2017, Volume 12, 3469-3485.	2.3	35
252	Protein tyrosin kinase and KCa++ channel: two faces of the same coin in LABA/LAMA synergy. , 2017, , .		1

#	ARTICLE	IF	CITATIONS
253	Clinical synergism of LABA/LAMA combinations in COPD patients. , 2017, , .		1
254	Benralizumab for the treatment of asthma. <i>Drugs of Today</i> , 2017, 53, 633.	1.1	6
255	Letter to the Editor: Can dog allergen immunotherapy reduce concomitant allergic sensitization to other furry animals? A preliminary experience. <i>European Annals of Allergy and Clinical Immunology</i> , 2017, 49, 92-96.	1.0	1
256	Clinical features and outcome of hospitalized patients with HSV-1 DNA in the lower respiratory tract. <i>New Microbiologica</i> , 2017, 40, 107-112.	0.1	1
257	Is Allergic Sensitization to Siberian Hamster Preventable in High-Risk Individuals Who Are Already Sensitized or Exposed to Furry Animals?. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2016, 26, 403-405.	1.3	1
258	Minimalist video-assisted thoracic surgery biopsy of mediastinal tumors. <i>Journal of Thoracic Disease</i> , 2016, 8, 3704-3710.	1.4	8
259	The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. <i>BioMed Research International</i> , 2016, 2016, 1-7.	1.9	8
260	Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. <i>Respiratory Research</i> , 2016, 17, 70.	3.6	71
261	Airflow obstruction: is it asthma or is it COPD?. <i>International Journal of COPD</i> , 2016, Volume 11, 3007-3013.	2.3	52
262	The effect of N -acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. <i>Respiratory Medicine</i> , 2016, 117, 190-197.	2.9	136
263	LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients. <i>Evidence-Based Medicine</i> , 2016, 21, 222-222.	0.6	9
264	Dysfunction of small airways and prevalence, airway responsiveness and inflammation in asthma: much more than small particle size of pet animal allergens. <i>Upsala Journal of Medical Sciences</i> , 2016, 121, 196-197.	0.9	1
265	Can pet keeping be considered the only criterion of exposure to cat/dog allergens in the first year of life?. <i>Allergologia Et Immunopathologia</i> , 2016, 44, 387-388.	1.7	7
266	An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network. <i>International Journal of Mycobacteriology</i> , 2016, 5, 244-247.	0.6	15
267	Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update. <i>Drug Safety</i> , 2016, 39, 501-508.	3.2	28
268	A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. <i>Chest</i> , 2016, 149, 1181-1196.	0.8	206
269	Chronic cat allergen exposure and low sensitization: Possible limitations in patient selection?. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1621-1622.	2.9	5
270	The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 733-744.	5.0	39

#	ARTICLE	IF	CITATIONS
271	Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 40, 95-103.	2.6	112
272	Assessment of pet exposure by questionnaires in epidemiological studies (but also in clinical) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702</i>	1.7	6
273	Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. <i>Drugs</i> , 2016, 76, 1257-1270.	10.9	36
274	Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 791-793.	3.8	7
275	The role of epsilon PKC in acute and chronic diseases: Possible pharmacological implications of its modulators. <i>Pharmacological Research</i> , 2016, 111, 659-667.	7.1	10
276	Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 55, 804-814.	2.9	54
277	Brain natriuretic peptide: Much more than a biomarker. <i>International Journal of Cardiology</i> , 2016, 221, 1031-1038.	1.7	51
278	Onset of action of budesonide/formoterol Spiromax [®] compared with budesonide/formoterol Turbuhaler [®] in patients with COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 39, 48-53.	2.6	7
279	Gastroesophageal reflux and <sc>COPD</sc> exacerbations: Is cholinergic [®] mediated oesophago [®] bronchial reflex a possible link?. <i>Respirology</i> , 2016, 21, 1496-1497.	2.3	1
280	Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1133-1146.	2.4	47
281	Do we really need asthma [®] “chronic obstructive pulmonary disease overlap syndrome?. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 977-983.	2.9	52
282	Dog allergen immunotherapy and allergy to furry animals. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 116, 590.	1.0	2
283	Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. <i>Respiratory Medicine</i> , 2016, 117, 150-153.	2.9	26
284	Interaction between corticosteroids and muscarinic antagonists in human airways. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 36, 1-9.	2.6	47
285	Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 977-988.	1.8	9
286	How many systemic reactions to skin prick tests could be preventable in defined conditions?. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 116, 174.	1.0	4
287	Serum- and Glucocorticoid-Inducible Kinase 1 Delay the Onset of Endothelial Senescence by Directly Interacting with Human Telomerase Reverse Transcriptase. <i>Rejuvenation Research</i> , 2016, 19, 79-89.	1.8	6
288	Occupational allergy to horse allergens: More than exposure to horses!. <i>International Journal of Occupational Medicine and Environmental Health</i> , 2016, 29, 721-723.	1.3	0

#	ARTICLE	IF	CITATIONS
289	Can the presence of cat/dog at home be considered the only criterion of exposure to cat/dog allergens? A likely underestimated bias in clinical practice and in large epidemiological studies. <i>European Annals of Allergy and Clinical Immunology</i> , 2016, 48, 61-4.	1.0	9
290	Chronic obstructive pulmonary disease and diabetes. <i>COPD Research and Practice</i> , 2015, 1, .	0.7	27
291	Analysis of exhaled breath fingerprints and volatile organic compounds in COPD. <i>COPD Research and Practice</i> , 2015, 1, .	0.7	33
292	Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 32, 15-23.	2.6	46
293	Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 33, 1-10.	2.6	14
294	Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 533-541.	2.4	36
295	Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 35-41.	3.1	8
296	Indacaterol for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 107-115.	1.8	6
297	Canakinumab for the treatment of chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 31, 15-27.	2.6	57
298	Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015, 12, 175-181.	1.6	73
299	Influence of ethnicity on response to asthma drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1089-1097.	3.3	14
300	Cardiovascular disease in patients with COPD. <i>Lancet Respiratory Medicine</i> , the, 2015, 3, 593-595.	10.7	22
301	Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. <i>Respiratory Medicine</i> , 2015, 109, 1019-1025.	2.9	21
302	QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1079-1090.	1.8	14
303	Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. <i>Drugs</i> , 2015, 75, 1575-1585.	10.9	30
304	Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. <i>Life Sciences</i> , 2015, 131, 44-50.	4.3	20
305	Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 529-539.	3.1	10
306	Novel glucocorticoid receptor agonists in the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1473-1482.	4.1	17

#	ARTICLE	IF	CITATIONS
307	Influence of <i>N</i> -acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. <i>European Respiratory Review</i> , 2015, 24, 451-461.	7.1	140
308	Searching for the synergistic effect between acclidinium and formoterol: From bench to bedside. <i>Respiratory Medicine</i> , 2015, 109, 1305-1311.	2.9	54
309	Pharmacological assessment of the onset of action of acclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. <i>European Journal of Pharmacology</i> , 2015, 761, 383-390.	3.5	31
310	Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma. <i>Drugs of Today</i> , 2015, 51, 469.	1.1	6
311	Urgent awake thoracoscopic treatment of retained haemothorax associated with respiratory failure. <i>Annals of Translational Medicine</i> , 2015, 3, 112.	1.7	0
312	The complex care of severe emphysema: role of awake lung volume reduction surgery. <i>Annals of Translational Medicine</i> , 2015, 3, 108.	1.7	8
313	The clinical use of regenerative therapy in COPD. <i>International Journal of COPD</i> , 2014, 9, 1389.	2.3	5
314	Pharmacological characterization of the interaction between acclidinium bromide and formoterol fumarate on human isolated bronchi. <i>European Journal of Pharmacology</i> , 2014, 745, 135-143.	3.5	80
315	Brain Natriuretic Peptide Protects against Hyperresponsiveness of Human Asthmatic Airway Smooth Muscle via an Epithelial Cell-Dependent Mechanism. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014, 50, 493-501.	2.9	20
316	Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 595-607.	5.0	8
317	Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. <i>Respiratory Medicine</i> , 2014, 108, 307-313.	2.9	5
318	Phosphodiesterase Inhibitors for Chronic Obstructive Pulmonary Disease: What Does the Future Hold?. <i>Drugs</i> , 2014, 74, 1983-1992.	10.9	26
319	Umeclidinium for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , 2014, 8, 665-671.	2.5	16
320	Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 961-977.	1.8	26
321	Diabetes mellitus among outpatients with COPD attending a university hospital. <i>Acta Diabetologica</i> , 2014, 51, 933-940.	2.5	40
322	Defining Phenotypes in COPD: An Aid to Personalized Healthcare. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 381-388.	3.8	46
323	New Treatments for COPD in the Elderly. <i>Current Pharmaceutical Design</i> , 2014, 20, 5968-5982.	1.9	9
324	Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 414-423.	2.5	80

#	ARTICLE	IF	CITATIONS
325	Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. <i>Respiratory Medicine</i> , 2013, 107, 848-853.	2.9	16
326	A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD. <i>Respiratory Medicine</i> , 2013, 107, 2014-2021.	2.9	12
327	The effect of indacaterol during an acute exacerbation of COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2013, 26, 630-634.	2.6	21
328	The influence of propofol, remifentanyl and lidocaine on the tone of human bronchial smooth muscle. <i>Pulmonary Pharmacology and Therapeutics</i> , 2013, 26, 325-331.	2.6	35
329	Awake Thoracoscopic Biopsy of Interstitial Lung Disease. <i>Annals of Thoracic Surgery</i> , 2013, 95, 445-452.	1.3	89
330	Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity. <i>Pulmonary Pharmacology and Therapeutics</i> , 2013, 26, 156-157.	2.6	7
331	Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit. <i>Respiratory Medicine</i> , 2013, 107, 1417-1422.	2.9	22
332	β ₂ -Agonist Therapy in Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 690-696.	5.6	221
333	Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 775-781.	1.8	32
334	Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. <i>Respiratory Medicine</i> , 2013, 107, 107-111.	2.9	10
335	Comorbidities of asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2013, 19, 36-41.	2.6	53
336	Inhaled corticosteroids for chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2489-2499.	1.8	28
337	Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. <i>European Respiratory Journal</i> , 2012, 40, 101-109.	6.7	179
338	Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study. <i>Respiratory Medicine</i> , 2012, 106, 249-256.	2.9	89
339	An update on bronchodilators in Phase I and II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1489-1501.	4.1	32
340	Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. <i>Current Opinion in Pharmacology</i> , 2012, 12, 300-308.	3.5	20
341	High Glucose Enhances Responsiveness of Human Airways Smooth Muscle via the Rho/ROCK Pathway. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2012, 47, 509-516.	2.9	66
342	Randomized comparison of awake nonresectional versus nonawake resectional lung volume reduction surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 143, 47-54.e1.	0.8	112

#	ARTICLE	IF	CITATIONS
343	Comparative effectiveness of drugs for chronic obstructive pulmonary disease. <i>Drugs of Today</i> , 2012, 48, 785.	1.1	28
344	Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. <i>Pulmonary Pharmacology and Therapeutics</i> , 2011, 24, 221-226.	2.6	40
345	Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2011, 20, 291-298.	2.3	36
346	Asthma and comorbid medical illness. <i>European Respiratory Journal</i> , 2011, 38, 42-49.	6.7	98
347	Combined Pulmonary Fibrosis and Emphysema: 3D Time-resolved MR Angiographic Evaluation of Pulmonary Arterial Mean Transit Time and Time to Peak Enhancement. <i>Radiology</i> , 2010, 254, 601-608.	7.3	40
348	Metabolic syndrome and risk of pulmonary involvement. <i>Respiratory Medicine</i> , 2010, 104, 47-51.	2.9	18
349	Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: <i>formeâ€fruste</i> of Churgâ€Strauss syndrome?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1389-1390.	5.7	13
350	Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 478-482.	2.6	27
351	A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 522-525.	2.6	11
352	Biomarkers of lung damage associated with tobacco smoke in induced sputum. <i>Respiratory Medicine</i> , 2009, 103, 1592-1613.	2.9	41
353	Serum CA 15-3 is increased in pulmonary fibrosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2009, 26, 54-63.	0.2	21
354	Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view. <i>Respiratory Medicine</i> , 2008, 102, 321-327.	2.9	30
355	HRCT and histopathological evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema. <i>Respiratory Medicine</i> , 2008, 102, 1753-1761.	2.9	54
356	Review: New perspectives in the treatment of idiopathic pulmonary fibrosis. <i>Therapeutic Advances in Respiratory Disease</i> , 2008, 2, 75-93.	2.6	25
357	Treating systemic effects of COPD. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 544-550.	8.7	29
358	Results of unilateral lung volume reduction surgery in patients with distinct heterogeneity of emphysema between lungs. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 129, 73-79.	0.8	15
359	Identification of HLA-DRPhe ²⁴⁷ as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlu ²⁶⁹ . <i>Respiratory Research</i> , 2005, 6, 94.	3.6	26
360	Completion lobectomy after bilateral lung volume reduction for emphysema: salvage option or fancy?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2004, 127, 1212-1214.	0.8	1

#	ARTICLE	IF	CITATIONS
361	Feasibility and Results of Awake Thoracoscopic Resection of Solitary Pulmonary Nodules. <i>Annals of Thoracic Surgery</i> , 2004, 78, 1761-1768.	1.3	244
362	Effect of Lung Volume Reduction Surgery for Severe Emphysema on Right Ventricular Function. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 489-494.	5.6	60
363	HLA-DP-unrestricted TNF- α release in beryllium-stimulated peripheral blood mononuclear cells. <i>European Respiratory Journal</i> , 2002, 20, 1174-1178.	6.7	28
364	Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: Cleavage of proteins with aspartate vs. glutamate at position 298. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 2832-2835.	7.1	497
365	Thoracoscopic Reduction Pneumoplasty for Severe Emphysema: Do Pleural Adhesions Affect Outcome?. <i>Thoracic and Cardiovascular Surgeon</i> , 1999, 47, 288-292.	1.0	11
366	Endothelial Nitric Oxide Synthase as a Potential Susceptibility Gene in the Pathogenesis of Emphysema in α 1-Antitrypsin Deficiency. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1999, 20, 441-447.	2.9	68
367	Unilateral thoracoscopic reduction pneumoplasty for asymmetric emphysema ¹ . <i>European Journal of Cardio-thoracic Surgery</i> , 1998, 14, 33-39.	1.4	11
368	Immunogenesis of Lung Granulomatosis: New Acquisitions. <i>International Journal of Immunopathology and Pharmacology</i> , 1996, 9, 77-77.	2.1	0